Mirati To Challenge EMA’s Rejection Of US-Approved Krazati

Drug Was Granted Accelerated Approval By US FDA In December 2022

Mirati Therapeutics said it disagreed with the European Medicines Agency’s decision that its lung cancer drug did not meet its conditional marketing authorization criteria.

Concept of EMA European Medicines Agency. Drugs evaluation and quality control.
The EMA says Krazati should not be approved in the EU • Source: Shutterstock

Mirati Therapeutics is to appeal against the European Medicines Agency’s recommendation that pan-EU marketing approval should be refused for Krazati (adagrasib), the company’s US-approved treatment for KRASG12C -mutated advanced non-small cell lung cancer (NSCLC).

Mirati was seeking a conditional marketing authorization for the drug, but the EMA said today that the medicine did not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

England: Pharma Firms To Benefit From Parallel HTA And Regulatory Pathway

 

The UK drug regulator and England’s health technology assessment agency have joined forces under an information sharing agreement, aimed at accelerating patient access to newly approved medicines by three to six months.

UK Medicines Shortages Inquiry Eyes Full Reshoring of Drug Manufacturing

 

A newly launched UK government inquiry is seeking to learn how viable it would be to bring back domestic control over the entire drug manufacturing pipeline.

Plans For EU Biotech Act Shift Up A Gear

 

Companies have until early November to respond to a public consultation from the European Commission on its planned Biotech Act, which it hopes will help unleash the potential of small and midsize enterprises in the bloc.

More from Geography

UK Medicines Shortages Inquiry Eyes Full Reshoring of Drug Manufacturing

 

A newly launched UK government inquiry is seeking to learn how viable it would be to bring back domestic control over the entire drug manufacturing pipeline.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

Pharma Cooperating With Trump On Direct Sale To Consumers, Pfizer CEO Says

 

Pfizer is in active discussions with Trump on MFN pricing and collaborating with peers on direct sales as an approach to lower drug prices, CEO Albert Bourla said.